The indication was restricted to only patients with DMD who are 4 years of age and older with a confirmed mutation in the DMD gene; the indication for non-ambulatory patients with DMD was removed.
Pharmaceutical Technology on MSN
FDA approves Sarepta’s updated Elevidys label for DMD
Sarepta has received US Food and Drug Administration (FDA) approval for updated prescribing information for Elevidys ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback